1.1Carbon at the A3 position
The sp² carbon forms bonds to both neighboring ring atoms and contributes a p orbital to the aromatic π system. The C–H site preserves the ring atom count and removes the hydrogen-bond acceptor at A3.
Generated automatically. Not reviewed by a person. Not legal advice or an opinion.
Questions about how individual parts of claim 1 might be changed. A question may describe something different from what the claim language recites, or a version of it; no view is offered on which.
The sp² carbon forms bonds to both neighboring ring atoms and contributes a p orbital to the aromatic π system. The C–H site preserves the ring atom count and removes the hydrogen-bond acceptor at A3.
The NH nitrogen bonds to both neighboring ring atoms. Its lone pair contributes two electrons to the aromatic π system, and its N–H bond provides a hydrogen-bond donor.
The scaffold bonds directly to the proximal sp carbon of —C≡CH. The triple bond places the terminal carbon along the attachment axis and gives the substituent a linear two-carbon geometry.
A neutral sulfur atom forms one single bond to each carbon flanking X and completes the macrocyclic path at that position. The two C–S bonds give this bridge a longer bond path than a C–O–C bridge.
A four-position saturated tether takes the form —CH2—S—CH2—CH2—. Sulfur bonds to the two adjacent methylene groups, maintaining a continuous four-atom path between the tether endpoints.
Further arrangements of the same subject matter, described here as of the publication date at the foot of this page.
A tetrahydrofuran-3-yl group replaces a 1,3-dioxolan-4-yl group at the same aryl attachment site through a direct carbon–carbon bond. Both substituents have five-membered rings, and the tetrahydrofuran ring contains one oxygen where the dioxolane ring contains two. A solution binding assay compares the resulting macrocycle with its dioxolane counterpart using the same concentration series.
A 5-methyl-1,2,4-oxadiazol-3-yl group replaces an R11 phenyl group at the bond to W. The oxadiazole connects to W through carbon 3, with methyl at carbon 5 and a cyclic acetal elsewhere on the macrocycle. A matched-pair assay measures how the change in aromatic ring size and heteroatom content affects MCL-1 binding.
Two matched macrocycles use saturated Y tethers of six and seven methylene units. Both tethers connect the same attachment atoms, and the pair uses identical X and W groups and pendant substituents. A ring-closing reaction joins the corresponding linear precursors at the same bond to produce a pair whose macrocyclic paths differ by one carbon atom.
An isothermal titration calorimeter measures binding between a purified macrocycle and the isolated MCL-1 binding domain. The protein occupies the sample cell, and the injection syringe delivers successive aliquots of the macrocycle in matched buffer. A ligand-into-buffer run measures dilution heat, which is subtracted before fitting the integrated binding heats for affinity and stoichiometry.
A program stores the heterocyclic core, the X and Y fragments, and the pendant groups as molecular graphs with labeled attachment atoms. It joins fragments at matching labels, checks atom valences, and counts the atoms along the closed path that contains Y. It assigns each structure a canonical identifier that preserves stereochemistry and removes duplicate entries before export.
A2 is C–H, A3 and A6 are carbon, and A4 is oxygen. The A4 oxygen forms two bonds within the heterocyclic ring.
A2 is nitrogen, A3 and A6 are carbon, and A4 is sulfur. The A4 sulfur forms two bonds to adjacent ring atoms and carries no attached oxygen.
X is N(Rx2), and Rx2 is unsubstituted cyclopropyl. The nitrogen bonds directly to one cyclopropyl carbon and to the two atoms that flank X in the macrocycle.
Y is —CH2—CH═CH—CH2— with Z geometry at the double bond. The two flanking methylene groups lie on the same side of the alkene, which fixes their relative orientation at that bond.
Passages reproduced word for word from two earlier-published U.S. patent documents, placed beside the language of claim 1. No characterization is offered. Each passage is marked A or B for the document it comes from; ¶ numbers are the paragraph numbers in the USPTO’s published full text of that document.
Exemplary alkyl groups include methyl, fluoromethyl, difluoromethyl, trifluoromethyl, cyclopropylmethyl, cyclopentylmethyl, ethyl, n-propyl, i-propyl, n-butyl, t-butyl, n-pentyl, 3-pentyl, heptyl, octyl, nonyl, decyl and dodecyl; preferred are methyl, difluoromethyl and i-propyl.A · US 7,652,144 B2 · ¶ 50
R1 represents phenyl; a phenyl-C1-C6 alkyl-, wherein the phenyl is unsubstituted or substituted with 1-4 (e.g., 1-2, 1, 2, 3 or 4) substituents independently selected from the group consisting of: halogen, nitro, hydroxyl, amino, cyano, C1-C6 alkyl, C1-C6 alkoxy, and C1-C6 haloalkyl, wherein the alkyl, alkoxy and haloalkyl may be optionally substituted with hydroxyl, —O—(C1-C4)-alkyl, oxo, amino, —NH—(C1-C4)-alkyl, or —N—[(C1-C6)-alkyl]2, or the alkyl, alkoxy and haloalkyl arB · US 2013/0116256 A1 · ¶ 12
R3 is optionally substituted aryl or heteroaryl, wherein the substituted aryl or substituted heteroaryl group is substituted by one or more substituents which may be the same or different and are selected from alkyl, aryl, aralkyl, hydroxy, hydroxyalkyl, alkoxy, aryloxy, aralkyloxy, carboxy, acyl, aroyl, halo, nitro, cyano, carboxy, alkoxycarboxyl, aryloxycarbonyl, aralkyloxycarbonyl, acylamino, aroylamino, alkylsulfonyl, arylsulfonyl, alkylsulfinyl, arylsulfinyl, alkylthio,A · US 7,652,144 B2 · ¶ 41
R1 represents phenyl, a phenyl-C1-C6 alkyl-, wherein the phenyl is unsubstituted or substituted with 1-4 (e.g., 1-2, 1, 2, 3 or 4) substituents independently selected from the group consisting of: halogen, nitro, hydroxyl, amino, cyano, a C1-C6 alkyl, a C1-C6 alkoxy, and a C1-C6 haloalkyl, wherein the alkyl, alkoxy and haloalkyl may be optionally substituted with hydroxyl, a —O—(C1-C4)-alkyl, oxo, amino, a —NH—(C1-C4)-alkyl, or a —N—[(C1-C6)-alkyl]2, or the alkyl, alkoxy andB · US 2013/0116256 A1 · claim 2
An empty cell means only that no passage was reproduced there.
Disease states associated with abnormally high physiological levels of cytokines such as TNF are treatable according to the invention.A · US 7,652,144 B2 · ¶ 3
Disease states associated with pathological conditions that are modulated by inhibiting enzymes, which are associated with secondary cellular messengers, such as cyclic AMP phosphodiesterase, are also treatable according to the invention Cyclic AMP phosphodiesterase is an important enzyme which regulates cyclic AMP levels and in turn thereby regulates other important biological reactions.A · US 7,652,144 B2 · ¶ 7
However, there are few kinds and numbers of drugs so far that can be clinically used for combating apoptosis and protecting cells, and their selectivity and targeting property are not satisfied, and therefore it is of great significance to continuously develop new, safe and effective drugs for combating apoptosis and protecting cells, and especially drugs with a novel mechanism of action.B · US 2013/0116256 A1 · ¶ 7
In order to develop new, safe and effective drugs for combating apoptosis and protecting cells, after conducting extensive experimental researches for a long term the inventors have found a group of hexenone compounds that have effects of combating apoptosis and protecting myocardial cells, and can be used for prophylaxis or treatment of diseases or disorders associated with cardiomyocyte apoptosis.B · US 2013/0116256 A1 · ¶ 8
patent.fyi, US 2026/0356848 A1, claim 1, first published 2026-11-20T08:11:50-05:00, https://patent.fyi/US20260356848/, SHA-256 ada04ad65f120d6a2b33033efed69f96dbaf1a597d609338aa948b2f913de481